Quoin Pharmaceuticals Ltd.: Form 20-F for the period ended Dec 31, 2021
Filed with the SEC on Apr 14, 2022 and accepted by EDGAR at Apr 13, 2022, 21:59 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2021-01-01 to 2021-12-31 | $0 | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 12 months2021-01-01 to 2021-12-31 | $1.6m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2021-01-01 to 2021-12-31 | $4.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 12 months2021-01-01 to 2021-12-31 | $1.1m | us-gaap:InterestExpense |
| Net income | 12 months2021-01-01 to 2021-12-31 | −$21.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2021-01-01 to 2021-12-31 | −$0.01 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2021-01-01 to 2021-12-31 | −$0.01 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2021-01-01 to 2021-12-31 | 1,584,905,594 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2021-01-01 to 2021-12-31 | −$5.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2021-12-31 | $7.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-12-31 | $8.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-12-31 | $9.4m | us-gaap:Assets |
| Total liabilities | At period end2021-12-31 | $8.7m | us-gaap:Liabilities |
| Shareholders' equity | At period end2021-12-31 | $657.0k | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2021-12-31 | 3,354,650,799 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001104659-22-045620. Last ingested by Listed: Nov 6, 2026, 18:24 ET. Listed shows no prices and gives no investment advice.